Want to join the conversation?
On June 4, $VRTX collaborated with Parion Sciences to develop investigational epithelial sodium channel inhibitors, including VX-371 and P-1055 for potential treatment of cystic fibrosis and other pulmonary diseases. $VRTX is responsible for all costs related to development and commercialization of the compounds.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.